Does Rallies show Form 4 insider transactions for ETON?

Yes. Rallies tracks ETON insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ETON research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ETON. It does not provide personalized investment advice.

ETON (Eton Pharmaceutcials, Inc. Common Stock) Stock Analysis - Insider Trades

Eton Pharmaceutcials, Inc. Common Stock (ETON) is a publicly traded Healthcare sector company. As of May 20, 2026, ETON trades at $33.86 with a market cap of $889.98M and a P/E ratio of -651.88. ETON moved +1.12% today. Year to date, ETON is +102.28%; over the trailing twelve months it is +68.06%. Its 52-week range spans $5.40 to $33.41. Analyst consensus is strong buy with an average price target of $45.67. Rallies surfaces ETON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ETON stock inside the company?

Recent ETON insider activity includes Gruber James R. sold 2.63K, Gruber James R. sold 39.08K, Krempa David sold 10.22K, Krempa David sold 6.80K, and Krempa David sold 16.98K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ETON Key Metrics

Key financial metrics for ETON
Metric	Value
Price	$33.86
Market Cap	$889.98M
P/E Ratio	-651.88
EPS	$-0.05
Dividend Yield	0.00%
52-Week High	$33.41
52-Week Low	$5.40
Volume	414.81K
Avg Volume	0
Revenue (TTM)	$86.93M
Net Income	$-1.48M
Gross Margin	54.77%

Recent ETON Insider Trades

Gruber James R. sold 2.63K (~$42.15K) on Aug 20, 2025.
Gruber James R. sold 39.08K (~$631.57K) on Aug 19, 2025.
Krempa David sold 10.22K (~$150.58K) on Jun 16, 2025.
Krempa David sold 6.80K (~$100.44K) on Jun 13, 2025.
Krempa David sold 16.98K (~$253.30K) on Jun 12, 2025.

Latest ETON News

Eton Pharmaceuticals Gains U.S. Rights to IMPAVIDO with September 2026 Launch — May 19, 2026
Eton Pharmaceuticals Posts 73% Q1 Sales Growth, Raises Guidance Above $120M — May 15, 2026
Eton Schedules Q1 Results Call May 14, Shares Surge 19.8% — May 4, 2026
Eton Pharmaceuticals Relaunches HEMANGEOL With Exclusive Anovo Distribution and $0 Co-pay — May 1, 2026
Eton Pharmaceuticals Names Judith Matthews as CFO Effective June 1, 2026 — Apr 16, 2026

ETON Analyst Consensus

3 analysts cover ETON: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.67.

Common questions about ETON

Who is trading ETON stock inside the company?: Recent ETON insider activity includes Gruber James R. sold 2.63K, Gruber James R. sold 39.08K, Krempa David sold 10.22K, Krempa David sold 6.80K, and Krempa David sold 16.98K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ETON?: Yes. Rallies tracks ETON insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ETON research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ETON. It does not provide personalized investment advice.